Myositis ossificans progressiva, left ankle
ICD-10 M61.172 is a billable code used to indicate a diagnosis of myositis ossificans progressiva, left ankle.
Myositis ossificans progressiva (MOP) is a rare genetic disorder characterized by the abnormal formation of bone in muscles, tendons, and other connective tissues. This condition typically presents with progressive muscle weakness and stiffness, often beginning in childhood or early adulthood. In the case of M61.172, the ossification occurs specifically in the left ankle region, leading to significant functional impairment. Patients may experience episodes of swelling, pain, and limited range of motion in the affected area. The underlying pathophysiology involves mutations in the ACVR1 gene, which plays a crucial role in bone morphogenetic protein (BMP) signaling, leading to inappropriate bone formation in soft tissues. Diagnosis is primarily clinical, supported by imaging studies that reveal heterotopic ossification. Management focuses on symptomatic relief, physical therapy, and avoiding invasive procedures that may exacerbate the condition. Understanding the complexities of MOP is essential for accurate coding and appropriate patient management.
Detailed clinical history, physical examination findings, and imaging results.
Patients presenting with progressive muscle weakness and pain in the left ankle.
Ensure documentation reflects the genetic basis of the condition and any associated comorbidities.
Genetic testing results and family history of myositis ossificans.
Patients with a family history of MOP or unexplained ossification.
Document the specific genetic mutations identified and their implications for treatment.
Used for follow-up visits for management of MOP.
Document history, examination, and medical decision-making.
Rheumatology and genetics specialties may require additional documentation related to genetic testing.
Myositis ossificans progressiva is a rare genetic disorder characterized by the abnormal formation of bone in muscles and connective tissues, leading to progressive muscle weakness and stiffness.
Diagnosis of M61.172 involves clinical evaluation, imaging studies to identify ossification, and genetic testing to confirm mutations in the ACVR1 gene.
